Ulf Schneider - PAREXEL International President

Dr. Ulf Schneider, Ph.D., is Chief Administrative Officer, Senior Vice President of Parexel International Corporationrationration since June 2000. From 1990 to 1992, he served as Director of Finance and Administration of PAREXEL Germany and from 1992 to 1996 he served as Vice President of Finance of PAREXEL Germany. Prior to joining PAREXEL, Dr. Schneider held several financial management positions at Schering AG, a pharmaceutical company, in Germany and was an Assistant Professor of Banking and Finance at the Berlin Technical University
Age: 57  President Since 2000      
781 487-9900  http://www.parexel.com
Schneider received his Masters degree in business administration and Ph.D. in business management from the Berlin Technical University.

Ulf Schneider Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Christopher FenimoreRegeneron Pharmaceuticals
Roxanne LaganoZoetis
James MichaudPerrigo Company Plc
Jatin ShahPerrigo Company Plc
Joyce LeeZoetis
Stefan WeiskopfZoetis
Svend AndersenPerrigo Company Plc
Ganadhish KamatDr Reddys Laboratories Ltd
Thomas GraneyVertex Pharmaceuticals Incorpor
Paul WeningerPerrigo Company Plc
Daniel PlewRegeneron Pharmaceuticals
James DillardPerrigo Company Plc
Roman TrawickiZoetis
John WesolowskiPerrigo Company Plc
Thomas FarringtonPerrigo Company Plc
John GrayVertex Pharmaceuticals Incorpor
Catherine KnuppZoetis
Charles MilsteinVertex Pharmaceuticals Incorpor
Alok SonigDr Reddys Laboratories Ltd
Heidi ChenZoetis
Glenn DavidZoetis

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Did you try this?

Run Portfolio Holdings Now


Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 200 shares of
a day ago
Traded for 14.76
Purchased over 50 shares of
a day ago
Traded for 53.37
Purchased few shares of
a day ago
Traded for 270.71
Purchased over 40 shares of
a day ago
Traded for 75.81
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Search macroaxis.com